GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (LTS:0O14) » Definitions » Debt-to-Asset

Merck KGaA (LTS:0O14) Debt-to-Asset : 0.20 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Merck KGaA Debt-to-Asset?

Merck KGaA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €625 Mil. Merck KGaA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €9,239 Mil. Merck KGaA's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €48,495 Mil. Merck KGaA's debt to asset for the quarter that ended in Dec. 2023 was 0.20.


Merck KGaA Debt-to-Asset Historical Data

The historical data trend for Merck KGaA's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck KGaA Debt-to-Asset Chart

Merck KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.29 0.24 0.21 0.20

Merck KGaA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.22 0.23 0.22 0.20

Competitive Comparison of Merck KGaA's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Debt-to-Asset falls into.



Merck KGaA Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Merck KGaA's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Merck KGaA's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck KGaA  (LTS:0O14) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Merck KGaA Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Merck KGaA's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck KGaA (LTS:0O14) Business Description

Address
Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Merck KGaA (LTS:0O14) Headlines

No Headlines